Synthesis, characterization and anticancer activity of new zinc(II), molybdate(II), palladium(II), silver(I), rhodium(III), ruthenium(II) and platinum(II) complexes of 5,6-diamino-4-hydroxy-2-mercaptopyrimidine

Add time:09/26/2019    Source:infona.pl

New complexes of 5,6-diamino-4-hydroxy-2-mercaptopyrimidine (Hdahmp), [Zn(Hdahmp) 2 Cl 2 ], [Zn(bpy)(dahmp)]Cl, [Zn(Hdahmp) 2 ]SO 4 , [Pd(Hdahmp)(dahmp)]Cl, [Pt(dahmp-H)] + n , [M(bpy)(dahmp]Cl, [M(bpy)(Hdahmp]Cl 2 (M(II)=Pd, Pt), [Ru(dahmp) 2 (PPh 3 ) 2 ], [Rh(dahmp) 2 (H 2 O) 2 ]Cl, [Ag 2 (Hdahmp) 2 ], cis-[MoO 2 (dahmp ∗ 3HCl) 2 ] and cis-[MoO 2 (Hdahmp)(DMF)Cl]Cl have been synthesized and characterized on the basis of elemental analyses, IR, NMR ( 1 H, 13 C, 31 P), UV–Vis and ESI-mass spectrometry, thermal and molar conductivity measurements. 5,6-Diamino-4-hydroxy-2-mercaptopyrimidine exhibits five different modes of chelation: (i) a neutral bidentate ligand through the cyclic nitrogen (N-3) and thione sulfur atoms, (ii) a mononegative bidentate ligand through the deprotonated cyclic nitrogen (N-1) and thione sulfur atoms, (iii) a mononegative bidentate ligand through the cyclic nitrogen (N-3) and deprotonated hydroxy centers, (iv) a tetradentate ligand through the cyclic nitrogens (deprotonated N-1, N-3), thione and deprotonated hydroxy oxygen centers, and (v) a mononegative bidentate through the deprotonated cyclic nitrogen (N-3) and ketonic oxygen atoms. The free Hdahmp and several of its complexes have been tested against the human serous ovarian cancer (OV-90) and human ovarian cancer (OVCAR-8) cell lines.

We also recommend Trading Suppliers and Manufacturers of SILVER MOLYBDATE (cas 13765-74-7). Pls Click Website Link as below: cas 13765-74-7 suppliers

Prev:Silver-decorated orthophosphate@bismuth molybdate heterostructure: An efficient photocatalyst with two visible-light active components
Next:Microstructural study of Ag2S doped SILVER MOLYBDATE (cas 13765-74-7) glass-nanocomposites)